BerGenBio ASA: Notice of Annual General Meeting

Bergen, Norway – 30 April 2024: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 23 May 2024 at 16:00 hours (CEST).


The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company’s website:


All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the person he appoints), or to attend the general meeting virtually.

Advance vote or proxy for the Annual General Meeting can be registered through the company’s website or VPS Investor Service within 21 May 2023 16:00 hours (CEST). Virtual participants need to be logged in to the meeting before 16:00 hours (CEST) 23 May 2023.

All shareholders will receive a reference number and a pin code required for registration through the company’s website. Reference number and pin code will be received either by VPS Investor Service or by post depending if the shareholder is registered as electronical user.

We encourage all shareholders to register as electronical user in VPS.


– END –

About BerGenBio ASA 

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


Martin Olin, CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.